PSIL: 1st Quarter 2022 Portfolio Review

Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. For the fund’s most recent standardized and month-end performance, please click www.advisorshares.com/etfs/psil.

Performance

The AdvisorShares Psychedelics ETF (NYSE: PSIL) just launched with an inception date of September 15, 2021. In the past quarter (Q1 of 2022), the Fund had a loss of -32.32% on its net asset value (NAV) and -33.33% on its market price.  PSIL also had losses in its few months of existence in 2021.

Performance has struggled, but the Fund’s overall performance is tied to the success of the very new, small and volatile psychedelics industry which includes biotech, pharmaceutical and mental health companies. While short term performance of these stocks has been down rather dramatically, we remain bullish on the longer-term prospects of being “early” investors in this rapidly developing industry.

Portfolio

New Positions

The Fund did not add any new positions in the past quarter, nor completely remove any positions from the Fund. As the stocks it holds are highly volatile, we are continuously managing the Fund and attempt to add value at times by adding to positions or trimming to maintain certain position sizes.

Contributors / Detractors

With negative performance for the Fund, virtually all holdings were down for the quarter. One bright spot was Numinus Wellness (OTC: NUMIF) as it gained at least a little bit, up 1.13% in 3 months. Among the Fund’s largest holdings, Cybin (NYSE American: CYBN) was down -31.23%, ATAI Life Sciences (NASDAQ: ATAI) was down -33.29%, Field Trip Health (NASDAQ: FTRP) lost -45.47%, and Mind Medicine (NASDAQ: MNMD) lost -41.67.

Top Holdings

Ticker Security Description Portfolio Weight %
CYBN CYBIN INC 10.52%
MNMD MIND MEDICINE MINDMED INC 10.23%
CMPS COMPASS PATHWAYS PLC 9.56%
ATAI ATAI LIFE SCIENCES NV 8.68%
FTRP FIELD TRIP HEALTH LTD 6.76%
GBNH GREENBROOK TMS INC 5.53%
NUMIF NUMINUS WELLNESS INC 5.10%
DMTTF SMALL PHARMA INC 5.06%
GHRS GH RESEARCH PLC 5.03%
DRUG BRIGHT MINDS BIOSCIENCES INC 4.46%

As of 03.31.2022. Cash is not included. Subject to change.

Please see our complete Fund holdings at advisorshares.com/etfs/psil. The holdings details are updated each market day.

Cheers,

Dan Ahrens
AdvisorShares
AdvisorShares Psychedelics ETF (PSIL) Portfolio Manager

 

Past Commentary

Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting www.advisorshares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor.

There is no guarantee that the Fund will achieve its investment objective. An investment in the Fund is subject to risk, including the possible loss of principal amount invested.

Psychedelic drugs, also known as hallucinogens, are a group of substances, including psilocybin, that are used to change and enhance sensory perceptions, thought processes, and energy levels. Psychedelic medicines, therapeutics, and healthcare treatments may be used in the treatment of illnesses such as depression, addiction, anxiety and post-traumatic stress disorder. Psychedelic medicine companies include life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that are part of the supply chain for psychedelics.

Psychedelics Companies Risk. Psychedelics companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may significantly affect a psychedelics company’s ability to secure financing, impact the market for psychedelics and business sales and services, and set limitations on psychedelics use, production, transportation, and storage. There can be no guarantees that such approvals or administrative actions will happen or be favorable for psychedelics companies, and such actions may be subject to lengthy delays, and may require length and expensive clinical trials. Additionally, therapies containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to delays in approval of, and increased expenses for, companies and any future therapeutic candidates they may develop. All of these factors and others may prevent psychedelics companies from becoming profitable, which may materially affect the value of certain Fund investments. In addition, psychedelics are subject to the risks associated with the biotechnology and pharmaceutical industries.

In Canada, certain psychedelic drugs, including psilocybin, are classified as Schedule III drugs under the Controlled Drugs and Substances Act (“CDSA”) and, as such, medical and recreational use is illegal under Canadian federal laws. In the United States, certain psychedelic drugs, including psilocybin, are classified as Schedule I drugs under the Controlled Substances Act (“CSA”) and the Controlled Substances Import and Export Act (the “CSIEA”) and, as such, medical and recreational use is illegal under the U.S. federal laws. There is no guarantee that psychedelic drugs or psychedelic-inspired drugs will ever be approved as medicines in either jurisdiction.

In the United States, scheduling determinations by the Drug Enforcement Agency (“DEA”) are dependent on Food and Drug Administration (“FDA”) approval of a substance or a specific formulation of a substance. Unless and until psilocybin, psilocin, or other psychedelics-based products receive FDA approval, such products may be prohibited from sale, which could limit the growth opportunities for certain portfolio companies of the Fund. Even if approved by the FDA, the manufacture, importation, exportation, domestic distribution, storage, sale, and legitimate use of such products will continue to be subject to a significant degree of regulation by the DEA.

Security prices of small cap companies may be more volatile than those of larger companies and therefore the Fund’s share price may be more volatile than those of funds that invest a larger percentage of their assets in securities issued by larger-cap companies. These risks are even greater for micro-cap companies.

Shares are bought and sold at market price (closing price) not NAV and are not individually redeemed from the Fund. Market price returns are based on the midpoint of the bid/ask spread at 4:00 pm Eastern Time (when NAV is normally determined), and do not represent the return you would receive if you traded at other times. 

Holdings and allocations are subject to risks and change.

The views in this commentary are those of the portfolio manager and many not reflect his views on the date this material is distributed or any time thereafter. These views are intended to assist shareholders in understanding their investments and do not constitute investment advice.